New Study of Investigational Alzheimer’s Disease
Treatment Enrolling Patients in Australia
New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in
Sydney, Australia – 31, August 2009
– It was announced today that a new global clinical
trial has begun enrolling patients with Alzheimer’s disease in NSW, Victoria, Queensland,
South Australia, and Western Australia.
The CONCERT study, is a new clinical trial that will test the efficacy of a unique investigational drug, dimebon (latrepirdine)*, in patients currently taking Aricept® (donepezil HCI tablets), the leading Alzheimer’s disease medication worldwide.
“Alzheimer’s is a complex disease and while current medications address symptoms for some patients, the long-term management of this disease would benefit from new treatment options.” said Professor Henry Brodaty, Professor of Ageing and Mental Health, University of New South Wales; Director, Aged Care Psychiatry and Head of the Memory Disorders Clinic, Prince of Wales Hospital.
“CONCERT is an important study because dimebon is thought to work differently than current medications and this study will evaluate whether adding it to one of the most commonly used Alzheimer’s medications will provide more effective symptomatic treatment to patients,” said Brodaty.
While a cure is still many years away, treatments that provide lasting effects, more complete symptomatic benefits or slow disease progression would be meaningful advances for patients and caregivers; for this reason there is an urgent need for patients to participate in clinical trials to help advance the understanding of how Alzheimer’s disease can be better treated.
According to Alzheimer’s Australia an estimated 230,000 Australians have dementia; of which 50-70% are Alzheimer’s disease (1), a devastating disease that hinders a patient’s ability to remember, learn, perform daily activities and relate to others. As the baby boomer population ages, the incidence of Alzheimer’s is expected to increase dramatically.
(1) Alzheimer’s Fact Sheet, Alzheimer’s Australi
For more information on eligibility and enrollment, patients and caregivers can call the
CONCERT study hotline toll-free at 1 800 235 526
About the CONCERT Study
CONCERT is an international, randomized, double-blind, placebo-controlled study that will
enroll approximately 1,050 patients with mild-to-moderate AD at approximately 100 sites in
the United States, Australia, New Zealand and Western Europe. Patients on a stable dose of
Aricept will be randomized to one of three treatment groups: dimebon 20 mg three times per
day, dimebon 5 mg three times per day or placebo.
The primary endpoints are the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog) and the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL), a measure of self-care and daily function.
The CONCERT study is sponsored by Pfizer and Medivation, Inc.
Dimebon (latrepirdine) is an investigational drug currently in Phase 3 development for the
treatment of Alzheimer’s disease and in clinical development for Huntington disease (HD).
The comprehensive Phase 3 clinical development program for Alzheimer’s disease is
evaluating the potential for dimebon to be used in broad applications including use alone, in
combination with existing medications and in patients at all stages of the disease.
Dimebon has a unique mechanism of action, distinct from currently available treatments. In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function.
Mitchondria are critical to brain cell functioning as they are the primary source of energy for cells. Drugs that protect mitochondria or restore their function could potentially be a valuable treatment approach in AD.
* Latrepirdine is the proposed generic (nonproprietary) name for dimebon
Journal of Global Pharma Technology NEWS & EVENTS PHARMA NEWS Pfizer goes to court to protect exclusive rights to sell Viagra Patent protection and product pipelines are top priorities for every pharmaceutical manufacturer, which is why Pfizer Inc. and Teva Pharmaceuticals International Ltd. will be in federal court in Norfolk, Va., starting Wednesday as Pfizer fights to keep e
Código Civil Im Ferid/Firsching/Dörner/Hausmann enthaltene geänderte Vorschriften. Disposiciones incluidas en el Ferid/Firsching/ Dörner/Hausmann que han sido objeto de modificación: Artículo 9, apartado 2, párrafo segundo Nueva redacción por el artículo 3.º dos de la Ley Orgánica 11/2003, de 29 de septiembre (BOE núm. 234, de 30 de septiembre): Art. 9. 2. (.) La